Ayrton Capital’s Sonnet BioTherapeutics SONN Stock Holding History

Ayrton Capital’s Portfolio SONN Stock Details SONN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,349	Closed	-$276K	–	79
2023 Q1	$276K	Buy	+4,349	New	+$704K	0.99%	19

Other funds holding SONN

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

MCG

McCollum Christoferson Group Amherst, New York $341M AUM 15.01% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Ayrton Capital's SONN Position: Q2 2023 in Review

Ayrton Capital sold out of Sonnet BioTherapeutics (SONN) in Q2 2023, closing a stake of 4,349 shares — an estimated $276K sold.

Ayrton Capital first reported a position in SONN in Q1 2023 and held it in 1 quarter. The position peaked at $276K in Q1 2023. 21 funds tracked by Wall St. Rank hold SONN as of Q2 2023.

Ayrton Capital reported no remaining Sonnet BioTherapeutics position as of Q2 2023 after selling out during the quarter.
Ayrton Capital sold 4,349 Sonnet BioTherapeutics shares in Q2 2023, an estimated $276K.
Ayrton Capital first reported a position in Sonnet BioTherapeutics in Q1 2023 and held it in 1 quarter.
Ayrton Capital's Sonnet BioTherapeutics position peaked at $276K in Q1 2023.
21 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q2 2023.

Based on Ayrton Capital's 13F filing for Q2 2023, filed 14 Aug 2023.